Literature DB >> 668810

Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle.

A M Grant, R J Marshall, S I Ankier.   

Abstract

In animals and man the antidysrhythmic agent disopyramide in primarily metabolised by mono-N-dealkylation. The effects of disopyramide and its N-dealkylated metabolite (MIP) have been investigated using isolated cardiac and nervous tissue, and their effects have been compared with the effects of other antidysrhythmic agents. Disopyramide, d,l-propranolol and quinidine all decreased both maximum driving frequency and developed tension in electrically driven guinea pit atria. MIP and procaine amide also decreased maximum driving frequency, but had a positive intropic effect. MIP was only 4 times less active than disopyramide in decreasing maximum driving frequency. There was no evidence that either disopyramide or MIP possessed beta-adrenoceptor antagonist properties. In superfused rat sciatic nerves, it has been shown that neither disopyramide nor MIP possesses significant local anaesthetic properties. Procaine amide and lignocaine were highly active in this test. The possible contribution of MIP to the actions of disopyramide in vivo is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 668810     DOI: 10.1016/0014-2999(78)90313-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.

Authors:  E Iisalo; L Aaltonen
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

Review 4.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

5.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 7.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

8.  Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle.

Authors:  F Vanhoutte; J Vereecke; E Carmeliet; N Verbeke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

9.  Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans.

Authors:  L Bergfeldt; K Schenck-Gustafsson; R Dahlqvist
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

10.  Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?

Authors:  M L Aitio; T Vuorenmaa
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.